SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Follow-up) — Ada Lovelace — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientAda Lovelace
Date of birth1815-12-10
IdentifiersMRN HR-NI031-SYN-TD; SSN (made up) 000-31-6729
Document date1851-09-08
AuthorConstance Whitley-Adeyemi, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Fourteen-week review after four cycles: restaging CT, blood counts, iron and thyroid, pain, and goals of care. [S]

History of Present Illness

Mrs. Lovelace returns a week after her fourth cycle. The restaging CT a week ago shows a partial response. She has had no bleeding. Her average pain is 3 of 10 on long-acting morphine 15 mg twice a day, now with a breakthrough dose only once or twice a week. She has mild tingling in her toes that does not affect walking or buttons. She tires for three or four days after each cycle. Her bowels are regular on the laxatives. She has no rash, diarrhea, cough, or cold intolerance. She is working most mornings. She has stopped betting and is meeting the social worker about her debts. The thyroid test due six weeks into treatment and the ferritin due after the iron infusions were not drawn; both were drawn today. [S]

ElementDetail
ResponsePartial response on CT after four cycles
PainAverage 3 of 10; breakthrough dose once or twice a week
NeuropathyMild tingling in the toes, no loss of function
WorkMathematics most mornings
Missed testsSix-week thyroid test and ferritin drawn today instead

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired for a few days after each cycle
NeurologicalPositiveMild tingling in the toes
EndocrineNegativeNo cold intolerance or weight gain
IntegumentaryNegativeNo rash
PsychiatricNegativeMood better; counseling helps

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Opium tincture (100 mg/mL opium, equivalent to 10 mg/mL morphine), 0.5 mL by mouth four to six times a day as needed for pain0.5 mL four to six times a day as neededOral route1849-06-03 to 1851-06-02completedS
Morphine sulfate oral solution 2 mg/mL, 5 mg (2.5 mL by oral syringe) every 4 hours as needed for pain5 mg every 4 hours as neededOral route1851-06-02activeS
Morphine sulfate extended-release 15 mg tablet, one tablet by mouth every 12 hours; swallow wholeevery 12 hoursOral route1851-06-16 to 1851-10-20completedS
Naloxone 4 mg nasal spray, one spray in a nostril for suspected opioid overdose; call 911one spray as needed for suspected overdose; repeat after 2 to 3 minutes if neededNasal route1851-06-02activeS
Senna 8.6 mg tablet, two tablets by mouth at nighttwo tablets at nightOral route1851-06-02activeS
Polyethylene glycol 3350, 17 g in water by mouth once or twice a dayonce daily, up to twice dailyOral route1851-06-02activeS
Acetaminophen 500 mg tablet, two tablets by mouth three times a day1 g three times a dayOral route1851-06-02activeS
Ferric carboxymaltose 750 mg intravenous infusion, two doses at the first two visits750 mg on two occasions two weeks apartIntravenous route1851-06-02 to 1851-06-17completedS
Pembrolizumab 200 mg intravenously every 3 weeksevery 3 weeksIntravenous route1851-06-30activeS
Carboplatin, dose to an AUC of 5 (650 mg), intravenously every 3 weeks for six cyclesevery 3 weeks for six cyclesIntravenous route1851-06-30 to 1851-10-13completedS
Paclitaxel 175 mg/m2 (275 mg) intravenously every 3 weeks for six cycles, with premedicationevery 3 weeks for six cyclesIntravenous route1851-06-30 to 1851-10-13completedS
Ondansetron 8 mg tablet, one tablet by mouth twice a day for three days after each chemotherapy cycle, then as neededtwice a day for three days after each cycle, then as neededOral route1851-06-30activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1851-09-08Body height165cmS
1851-09-08Body weight54kgS
1851-09-08Body mass index (BMI) [Ratio]19.8kg/m2S
1851-09-08Systolic blood pressure112mm[Hg]S
1851-09-08Diastolic blood pressure70mm[Hg]S
1851-09-08Heart rate80/minS
1851-09-08Respiratory rate16/minS
1851-09-08Body temperature36.7CelS
1851-09-08Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1851-09-08Hemoglobin [Mass/volume] in Blood10.6g/dL12-15.5 g/dLLowS
1851-09-08Leukocytes [#/volume] in Blood by Automated count3.810*3/uL4-11 10*3/uLLowS
1851-09-08Neutrophils [#/volume] in Blood by Automated count1.910*3/uL1.8-7.7 10*3/uLNormalS
1851-09-08Platelets [#/volume] in Blood by Automated count17210*3/uL150-400 10*3/uLNormalS
1851-09-08Creatinine [Mass/volume] in Serum or Plasma0.72mg/dL0.57-1 mg/dLNormalS
1851-09-08Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L7-35 U/LNormalS
1851-09-08Thyrotropin [Units/volume] in Serum or Plasma3.4m[IU]/L0.45-4.5 mIU/LNormalS
1851-09-08Ferritin [Mass/volume] in Serum or Plasma210ng/mL15-150 ng/mLHighS
1851-09-08Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1846)/1.73 sq M112mL/min/{1.73_m2}60 or moreNormalS
1851-09-08Pain severity - 0-10 verbal numeric rating [Score] - Reported3{score}S
1851-09-08Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S

Physical Exam

Vital signs recorded on 1851-09-08; see the Vital Signs section. [S]

SystemFinding
GeneralWell, not sedated; blood pressure 112/70, pulse 80, weight 54.0 kg
NeckNo thyroid enlargement
RespiratoryClear
NeurologicalLight touch slightly reduced at the toes; vibration and strength normal; grade 1 neuropathy

Problems

ProblemClinical statusVerificationCodeProvenance
Bleeding between periods and after intercourse, with heavier periods, a watery blood-stained discharge and a constant pelvic ache, for about five months; average pain 7 of 10 despite her opium tincture; a friable cervical mass found on examination and biopsied; cause not yet established at intakeresolvedconfirmed N93.8S — Synthetic presenting problem anchored to her documented final illness; superseded by the diagnosis at the second visit.
Iron deficiency anemia from chronic blood loss: hemoglobin 8.4 g/dL, mean cell volume 74 fL, ferritin 5 ng/mL, with tiredness and breathlessness on stairsactiveconfirmed D50.0S — Synthetic modern finding anchored to her documented final illness.
Adenocarcinoma of the endocervix, usual (HPV-associated) type, HPV 18 positive, FIGO 1843 stage IVB: a 5.2 cm tumor with left parametrial invasion, metastases to left pelvic and para-aortic lymph nodes, and bilateral lung metastases on MRI and PET-CT; PD-L1 combined positive score 5, mismatch repair proficient, HER2 1+; treated with palliative pelvic radiation for bleeding and carboplatin, paclitaxel and pembrolizumab, with specialist palliative care from diagnosisactiveconfirmed C53.0S — Synthetic modern diagnosis made at the second visit, anchored to her documented uterine cancer; the cervical site is a synthetic choice.
Cancer-related pelvic pain, nociceptive and visceral, from the cervical tumor and its left parametrial extensionactiveconfirmed G89.3S — Synthetic modern diagnosis made at the second visit.
Long-term prescribed opioid therapy: opium tincture for recurrent pelvic and abdominal pain for about two years, measured at times with a household spoon, converted at intake to measured oral morphine; no opioid use disorder on a DSM-5 assessment; naloxone suppliedactiveconfirmed Z79.891S — Synthetic modern history anchored to her documented laudanum and opium; not a claim about her real dosing.
Drug-induced constipation from long-acting morphine and ondansetron, a week after the first chemotherapy cycle: no bowel movement for five days, with bloating and cramping but passing wind, without vomiting; no bowel obstruction on examination; potassium and calcium normal; resolved with laxativesresolvedconfirmed K59.03S — Synthetic adverse drug effect; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBlood count (hemoglobin, white cells, neutrophils, platelets)Before each chemotherapy cycle and at each visitCompleted todayHemoglobin 10.6 g/dL, white cells 3.8, neutrophils 1.9, platelets 172
LaboratoryCreatinine, eGFR and ALTBefore each cycleCompleted todayCreatinine 0.72 mg/dL, eGFR 112, ALT 26 U/L
LaboratoryTSH and free T4 on pembrolizumabBaseline, then every 6 weeksCompleted todayTSH 3.4 mIU/L. Protocol deviation: the TSH and free T4 due six weeks after baseline were not drawn, because they were left to be added to the cycle 3 blood tests and were not ordered; drawn today, twelve weeks after baseline. No harm resulted: TSH is normal and she has no thyroid symptoms. Corrective action: a standing order for TSH and free T4 every six weeks while she takes pembrolizumab
LaboratoryFerritin after intravenous iron6 to 8 weeks after the infusionsCompleted todayFerritin 210 ng/mL. Protocol deviation: the ferritin due 6 to 8 weeks after the second infusion was not drawn at the preventive visit, which fell in that window; drawn today, twelve weeks after. No harm resulted: stores are replete and hemoglobin is rising. Corrective action: list post-infusion tests on the problem list with their due dates
ExaminationVaginal bleeding and transfusion needEvery visitCompleted todayNo bleeding
ExaminationImmune-related adverse effects: rash, diarrhea, cough, fatigueEvery visitCompleted todayNone
ExaminationPeripheral neuropathy on paclitaxelBefore each paclitaxel cycleCompleted todayGrade 1 sensory neuropathy of the toes
ImagingRestaging CT of chest, abdomen and pelvisEvery 2 to 3 cycles during first-line therapy, then every 3 monthsCompleted todayCT a week ago: partial response
SurveyPain intensity (0 to 10) and functionEvery visitCompleted todayAverage 3 of 10
Medication safetyOpioid adverse effects: sedation, confusion, nauseaEvery visitCompleted todayNo sedation
Medication safetyBowel regimen and constipationEvery visitCompleted todayRegular
Medication safetyNaloxone, locked storage, one prescriber, prescription monitoring checkAt each opioid change, and every 3 monthsCompleted todayNaloxone in date; locked storage; monitoring check clear
Medication safetySigns of opioid use disorderEvery visitCompleted todayNone
SurveyDepression screen (PHQ-9) and distressPeriodicallyCompleted todayPHQ-9 7
ReferralSpecialist palliative careOngoing alongside cancer treatmentCompleted todayPalliative care physician joined today's conversation
Self-managementGoals-of-care conversationAt diagnosis, at each restaging, and with any changeCompleted todayRecorded; resuscitation not to be attempted; all other treatment continues

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (2026); Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826; Colombo N, et al. N Engl J Med 2021;385:1856-1867) (2021); Palliative Care for Patients With Cancer: ASCO Guideline Update (Sanders JJ, et al. J Clin Oncol 2024;42:2336-2357) (2024); Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline (Paice JA, et al. J Clin Oncol 2023;41:914-930) (2023); Patient-Clinician Communication: ASCO Guideline Update (Gilligan T, et al. J Clin Oncol 2026;44:1040-1057) (2026); CMID: Clinical Monitoring Intelligence Database, anemia monograph (2026); Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (Schneider BJ, et al. J Clin Oncol 2021;39:4073-4126) (2021)

Follow-up: Cycles 5 and 6 every three weeks. Review a week after the last cycle. Next scheduled visit 1851-10-20: twenty-week review after the last chemotherapy cycle: blood counts, thyroid on pembrolizumab, tapering morphine, mood and her work. [S]